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■ EDITORIAL ■
Ectopic pregnancy, where the gestational sac is located
outside the uterus, is the most common life-threatening
emergency in early pregnancy [1]. Although recent reports
have shown a continuous increase in its incidence, mor-
tality from ectopic pregnancy declined by almost 90%
from 1979 to 1992 [2]. This reduction was primarily the
result of earlier diagnosis, i.e. before the occurrence of
hemoperitoneum and/or more severe conditions such as
hypovolemic shock. Earlier diagnosis is made possible
by the availability of sensitive and specific radioimmu-
noassays for human chorionic gonadotropin (hCG),
serum progesterone screening, high-resolution trans-
vaginal ultrasonography (TVS), and most importantly,
laparoscopy. The most common extrauterine site for
embryo implantation is the fallopian tube, but the con-
ceptus may implant in the ovaries, cervix, abdomen, or
at interstitial or cornual sites. The latter are considered
to be unusual ectopic pregnancies [3] and often result in
a more complicated clinical course, including difficulty
in making an early and accurate diagnosis, an incon-
sistent therapeutic approach, and an unpredictable
outcome, leading to a risky, life-threatening status.
In this issue, Su et al [4] reports on a rare case of a
primary ectopic pregnancy that took place in the ovary
(primary ovarian pregnancy) in a woman aged 22 years,
who subsequently received treatment with methotrex-
ate (MTX). This patient’s condition fulfilled the follow-
ing strict criteria: (1) hemodynamic stability, (2) no
severe or persistent abdominal pain, (3) commitment
to follow-up until the ectopic pregnancy resolved, and
(4) normal baseline liver and renal function tests, and
no contraindications to MTX treatment [3]. Although
fixed, multiple-dose MTX was given, the patient failed to
respond to treatment and eventually underwent laparo-
scopic surgery to allow for an accurate diagnosis of 
the primary ovarian pregnancy, which was followed by
wedge resection of the ectopic pregnancy. The authors
claimed that MTX was not suitable for first-line treat-
ment of ovarian pregnancy, and that an accurate pre-
operative diagnosis of primary ovarian pregnancy might
help in the decision-making process. Early surgery and
avoidance of other useless and possibly harmful thera-
peutic strategies, such as conservative observation or
medical treatment by systemic MTX injections, could
thus be avoided [4].
We fully understand the key points emphasized by
the authors, but many controversial issues require further
attention. First, why did the authors select multiple-dose
MTX treatment in place of single-dose MTX treatment
to manage the ectopic pregnancy, which was originally
thought to be an uncomplicated case? A recent report
based on a systematic review and meta-analysis found
that single-dose MTX might be more acceptable for the
management of tubal ectopic pregnancies, since there
was no significant difference in the treatment success
rates between single-dose and multiple-dose MTX [5].
Two trials involving 159 women compared single-dose
and the fixed multiple-dose MTX regimens [6,7] and
showed no significant difference in treatment success
(relative risk, 0.99; 95% confidence interval, 0.89–1.10)
[5]. Mean serum hCG concentrations varied between
2,230–2,973 and 2,180–2,244 IU/L, respectively [5].
In addition, another report highlighted the potential
for tubal damage associated with multiple-dose MTX
therapy [8], since free passage through the ipsilateral
tube (examined by hysterosalpingography) was observed
in 17 of 30 cases (56.7%) after multiple-dose treatment,
compared with 26 of 31 cases (83.9%) after single-
dose MTX therapy. The patency of the contralateral tube
was higher after single-dose than multiple-dose MTX
treatment. Although the main cause of tubal damage
is still under debate, and the definitive mechanism of
tubal obstruction induced by multiple-dose MTX has
yet to be clarified, a possible mechanism was proposed
[8]: in terms of the trophoblastic repair and damage
cycle found at tubal ectopic pregnancy sites [9], a single
dose of MTX may disrupt cell division in highly mitotic
placental cells, and then initiate the repair process, whilst
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repeated doses over time, as in multiple-dose regimens,
could have a negative impact on both the placental bed
and the initial repair process in the tubal epithelium
[8]. The risks and benefits should be carefully weighed
when deciding whether to use single- or multiple-dose
MTX for the management of an ectopic pregnancy.
Second, we presume that the authors initially con-
sidered this to be a case of tubal pregnancy, and they,
therefore, treated the patient as a low-risk tubal preg-
nancy and thus suitable for medical (rather than surgi-
cal) treatment [4]. Unfortunately, multiple-dose MTX
treatment did not achieve the intended results, there-
fore raising the concept, mentioned by the authors, that
primary ovarian pregnancy is not a medical illness. We
do not completely agree with this concept. From the
scientific point of view, this case would have been better
considered as a pregnancy of unknown location (PUL).
A PUL occurs when there is a positive pregnancy test
with no signs of intra- or extrauterine pregnancy on TVS.
In addition, the woman should have no signs of intra-
abdominal bleeding or evidence of hemoperitoneum
on an ultrasound scan [10]. A recent issue of the journal
Ultrasound Obstetrics and Gynecology (2006) published a
consensus statement on PUL [10]; the important con-
clusions included: (1) using modern imaging tools
(TVS), the incidence of PUL is less than 15%; (2) clini-
cally stable women with a PUL should initially be man-
aged expectantly; (3) the initial serum hCG level is not
predictive of PUL outcome, but mathematical models
based on the hCG ratio have been developed to pre-
dict PUL outcome; (4) in most cases, uterine curettage
should not play a role in the classification of PULs; and
(5) although a single-visit approach to the management
of PULs is not appropriate, visits at too frequent inter-
vals might also be inappropriate [10]. The number and
interval of visits for the optimal clinical management
of women with PULs is still unknown.
In conclusion, we would like to use the consensus
statement from The Practice Committee of the American
Society for Reproductive Medicine as our final opinion
on the medical treatment of women with primary ovar-
ian pregnancies [6]; that is, a primary ovarian preg-
nancy can only be diagnosed definitively at the time of
surgical exploration, including laparoscopy, and MTX
is, therefore, not a suitable first-line treatment for this
condition. Laparoscopy is considered to be the gold
standard for the diagnosis of ectopic pregnancies and
seems to be superior to other diagnostic and thera-
peutic methods, because it is minimally invasive, cost-
effective, useful in treatment, and only takes a short
time [11–13]. However, it is necessary to bear in mind
that there is no consensus on appropriate intervention
rates in women with PUL because of the difficulty in
accurately distinguishing between primary ovarian preg-
nancy and PUL. A clinical audit should be regularly
carried out to determine the rate of emergency surgery
carried out because of undetected ectopic pregnancies,
and the rate of unnecessary interventions, such as nega-
tive laparoscopic examinations [10].
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